1. Home
  2. BCYC vs STRO Comparison

BCYC vs STRO Comparison

Compare BCYC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$4.01

Market Cap

291.8M

Sector

Health Care

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$18.36

Market Cap

332.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCYC
STRO
Founded
2009
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
291.8M
332.8M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
BCYC
STRO
Price
$4.01
$18.36
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$13.90
$31.33
AVG Volume (30 Days)
265.8K
261.7K
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$38,419,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$0.72
52 Week High
$9.16
$43.85

Technical Indicators

Market Signals
Indicator
BCYC
STRO
Relative Strength Index (RSI) 44.16 30.17
Support Level $3.87 $10.34
Resistance Level $4.21 $26.35
Average True Range (ATR) 0.18 1.12
MACD -0.01 -0.07
Stochastic Oscillator 1.03 3.39

Price Performance

Historical Comparison
BCYC
STRO

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: